Increased eosinophil counts have been recognised to be linked to asthma severity and are a risk factor for asthma exacerbations. Therefore, decreasing eosinophil count by targeting the interleukin-5-mediated signalling pathway could help to reduce airway inflammation and improve asthma treatment control. In The Lancet Respiratory Medicine, Mario Castro and colleagues1 report data from two large, randomised, placebo-controlled trials, in which reslizumab, a neutralising monoclonal antibody for interleukin 5, was safe and effective in patients with severe eosinophilic asthma.
Recent Posts
- A survey of severe asthma in Canada: results from the CASCADE practice reflective program
- 17q21 Variants Disturb Mucosal Host Defense in Childhood Asthma
- TL1A is an epithelial alarmin that cooperates with IL-33 for initiation of allergic airway inflammation
- New for Journal of Asthma online now on Taylor & Francis Online
- The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma